INSM
BEARISH
$154.81
Live
Insmed Incorporated · NASDAQ
Target $212.15
(+37.0%)
$63.81
52W Range
$212.75
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$33.42B
P/E
N/A
ROE
-249.3%
Profit margin
-210.5%
Debt/Equity
1.01
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Insmed Incorporated exhibits a weak deterministic health profile with a Piotroski F-Score of 3/9, indicating significant fundamental instability. While the company shows explosive revenue growth of 152.6%, this is offset by extreme valuation metrics (Price/Sales of 55.10) and a consistent track record of missing earnings estimates (0/4 beats in the last year). The stark disconnect between the 'Strong Buy' analyst consensus and the bearish insider activity—including significant sales by the CEO and COO—suggests a high-risk speculative profile rather than a value-driven investment.
Key Strengths
Hyper-growth revenue increase of 152.60% YoY
Strong gross margins of 79.73% typical of high-value biotech
Robust short-term liquidity with a current ratio of 3.83
Strong long-term price appreciation (402.3% over 5 years)
High analyst conviction with a 'Strong Buy' consensus
Key Risks
Extreme valuation with a Forward P/E of 211.70 and P/S of 55.10
Severe lack of profitability with a profit margin of -210.54%
Chronic failure to meet earnings expectations (0/4 recent beats)
Bearish insider sentiment with $29.76M in net sales by executives
Negative ROE of -249.28% indicating poor capital efficiency
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
31
Weak
10
75
40
30
0
AI Verdict
Speculative Growth
Key drivers: Revenue Growth, Valuation Bubble, Fundamental Weakness, Insider Divergence
Confidence
90%
Value
10/100
Graham Number is N/A due to negative earnings; stock trades at a massive premium to book and sales.
Positives
No standout positives identified.
Watchpoints
- P/S ratio of 55.10 is unsustainable
- P/B ratio of 44.89 is extreme
- Forward P/E of 211.70
Future
75/100
Growth is the primary driver, but efficiency is lacking.
Positives
- 152.6% YoY Revenue growth
- Strong analyst target price of $212.15
Watchpoints
- Consistent earnings misses suggest growth is not translating to profit
Past
40/100
Historical price action is bullish, but historical earnings performance is poor.
Positives
- Strong 3Y and 5Y price returns
Watchpoints
- 25-quarter history of frequent earnings misses
- Negative EPS progression
Health
30/100
Low Piotroski score indicates deteriorating fundamental health.
Positives
- Current ratio of 3.83 provides a liquidity cushion
Watchpoints
- Piotroski F-Score of 3/9 (Weak)
- Deeply negative ROE and ROA
Dividend
0/100
Company is in a growth/burn phase; no capital returned to shareholders.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$154.81
Analyst Target
$212.15
Upside/Downside
+37.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for INSM and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
INSM
Insmed Incorporated
Primary
|
+402.3% | +817.7% | +138.9% | -4.6% | +11.1% | -4.7% |
|
GEHC
GE HealthCare Technologies Inc.
Peer
|
+22.2% | -9.0% | +12.5% | -1.6% | +0.3% | +3.6% |
|
A
Agilent Technologies, Inc.
Peer
|
+11.4% | -11.3% | -10.7% | +12.8% | -2.2% | -3.3% |
|
ALC
Alcon Inc.
Peer
|
+8.8% | +9.9% | -9.6% | -12.6% | +0.1% | +1.6% |
|
BIIB
Biogen Inc.
Peer
|
-34.2% | -34.1% | +34.0% | +30.9% | -2.5% | -0.3% |
INS
Insmed Incorporated
Primary
5Y
+402.3%
3Y
+817.7%
1Y
+138.9%
6M
-4.6%
1M
+11.1%
1W
-4.7%
GEH
GE HealthCare Technologies Inc.
Peer
5Y
+22.2%
3Y
-9.0%
1Y
+12.5%
6M
-1.6%
1M
+0.3%
1W
+3.6%
A
Agilent Technologies, Inc.
Peer
5Y
+11.4%
3Y
-11.3%
1Y
-10.7%
6M
+12.8%
1M
-2.2%
1W
-3.3%
ALC
Alcon Inc.
Peer
5Y
+8.8%
3Y
+9.9%
1Y
-9.6%
6M
-12.6%
1M
+0.1%
1W
+1.6%
BII
Biogen Inc.
Peer
5Y
-34.2%
3Y
-34.1%
1Y
+34.0%
6M
+30.9%
1M
-2.5%
1W
-0.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
211.7
PEG Ratio
N/A
P/B Ratio
44.89
P/S Ratio
55.1
EV/Revenue
53.91
EV/EBITDA
-33.34
Market Cap
$33.42B
Profitability
Profit margins and return metrics
Profit Margin
-210.54%
Operating Margin
-94.64%
Gross Margin
79.73%
ROE
-249.28%
ROA
-28.99%
Growth
Revenue and earnings growth rates
Revenue Growth
+152.6%
Earnings Growth
N/A
Q/Q Revenue Growth
+152.62%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.01
Moderate
Current Ratio
3.83
Strong
Quick Ratio
3.35
Excellent
Cash/Share
$6.63
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.3B
Gross Margin
83.2%
Op. Margin
-94.6%
Net Margin
-124.5%
Total Assets
$2.3B
Liabilities
$1.5B
Equity
$0.7B
Debt/Equity
2.06x
Operating CF
$-0.2B
CapEx
$-0.0B
Free Cash Flow
$-0.3B
FCF Yield
107%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-19
$-1.54
-31.9% surprise
2025-10-30
$-1.75
-27.8% surprise
2025-08-07
$-1.7
-29.6% surprise
Healthcare Sector Comparison
Comparing INSM against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-249.28%
This Stock
vs
-46.09%
Sector Avg
+440.9%
(Excellent)
Profit Margin
-210.54%
This Stock
vs
-19.58%
Sector Avg
+975.1%
(Superior)
Debt to Equity
1.01
This Stock
vs
4.1
Sector Avg
-75.2%
(Less Debt)
Revenue Growth
152.6%
This Stock
vs
88.16%
Sector Avg
+73.1%
(Fast Growth)
Current Ratio
3.83
This Stock
vs
3.58
Sector Avg
+7.0%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
INSM
Insmed Incorporated
|
BEARISH | $33.42B | - | -249.3% | -210.5% | $154.81 | |
|
GEHC
GE HealthCare Technologies Inc.
|
NEUTRAL | $33.27B | 16.2 | 22.4% | 10.1% | $72.91 | Compare |
|
A
Agilent Technologies, Inc.
|
NEUTRAL | $38.29B | 30.28 | 20.6% | 18.8% | $135.05 | Compare |
|
ALC
Alcon Inc.
|
NEUTRAL | $39.59B | 38.6 | 4.8% | 10.3% | $80.29 | Compare |
|
BIIB
Biogen Inc.
|
NEUTRAL | $26.91B | 20.83 | 7.4% | 13.1% | $183.33 | Compare |
INSM
Insmed Incorporated
BEARISH
Mkt Cap
$33.4B
P/E
-
ROE
-249.3%
Price
$154.81
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | LEWIS WILLIAM H | Chief Executive Officer | Sale | 10,699 | $1,746,336 |
| 2026-04-06 | LEWIS WILLIAM H | Chief Executive Officer | Option Exercise | 10,699 | $266,840 |
| 2026-04-01 | ADSETT ROGER | Chief Operating Officer | Sale | 88,060 | $14,497,651 |
| 2026-04-01 | ADSETT ROGER | Chief Operating Officer | Option Exercise | 88,060 | $1,282,154 |
| 2026-03-30 | SMITH MICHAEL ALEXANDER | Officer | Sale | 19,638 | $2,964,945 |
| 2026-03-30 | SMITH MICHAEL ALEXANDER | Officer | Option Exercise | 19,638 | $486,582 |
| 2026-03-19 | LEWIS WILLIAM H | Chief Executive Officer | Sale | 10,699 | $1,535,542 |
| 2026-03-19 | LEWIS WILLIAM H | Chief Executive Officer | Option Exercise | 10,699 | $266,840 |
| 2026-03-05 | LEWIS WILLIAM H | Chief Executive Officer | Sale | 10,699 | $1,562,328 |
| 2026-03-05 | LEWIS WILLIAM H | Chief Executive Officer | Option Exercise | 10,699 | $266,840 |
| 2026-03-03 | SHAROKY MELVIN A | Director | Gift | 100 | - |
| 2026-02-25 | SHAROKY MELVIN A | Director | Gift | 1,072 | - |
| 2026-02-24 | SMITH MICHAEL ALEXANDER | Officer | Sale | 24,774 | $3,859,157 |
| 2026-02-24 | SMITH MICHAEL ALEXANDER | Officer | Option Exercise | 20,248 | $345,633 |
| 2026-02-23 | BRENNAN DAVID R | Director | Gift | 6,000 | - |
LEWIS WILLIAM H
Chief Executive Officer
2026-04-06
10,699 shares
·
$1,746,336
LEWIS WILLIAM H
Chief Executive Officer
2026-04-06
10,699 shares
·
$266,840
ADSETT ROGER
Chief Operating Officer
2026-04-01
88,060 shares
·
$14,497,651
ADSETT ROGER
Chief Operating Officer
2026-04-01
88,060 shares
·
$1,282,154
SMITH MICHAEL ALEXANDER
Officer
2026-03-30
19,638 shares
·
$2,964,945
SMITH MICHAEL ALEXANDER
Officer
2026-03-30
19,638 shares
·
$486,582
LEWIS WILLIAM H
Chief Executive Officer
2026-03-19
10,699 shares
·
$1,535,542
LEWIS WILLIAM H
Chief Executive Officer
2026-03-19
10,699 shares
·
$266,840
LEWIS WILLIAM H
Chief Executive Officer
2026-03-05
10,699 shares
·
$1,562,328
LEWIS WILLIAM H
Chief Executive Officer
2026-03-05
10,699 shares
·
$266,840
SHAROKY MELVIN A
Director
2026-03-03
100 shares
SHAROKY MELVIN A
Director
2026-02-25
1,072 shares
SMITH MICHAEL ALEXANDER
Officer
2026-02-24
24,774 shares
·
$3,859,157
SMITH MICHAEL ALEXANDER
Officer
2026-02-24
20,248 shares
·
$345,633
BRENNAN DAVID R
Director
2026-02-23
6,000 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
20 analysts
Barclays
2026-04-01
Overweight
Overweight
Morgan Stanley
2026-03-30
Equal-Weight
Overweight
HC Wainwright & Co.
2026-03-26
Buy
Buy
Mizuho
2026-03-25
Outperform
Outperform
Leerink Partners
2026-03-24
Outperform
Outperform
Stifel
2026-03-24
Buy
Buy
Wells Fargo
2026-03-24
Overweight
Overweight
B of A Securities
2026-03-24
Buy
Buy
Wells Fargo
2026-03-23
Overweight
Overweight
Mizuho
2026-02-24
Outperform
Outperform
Past News Coverage
Recent headlines mentioning INSM from our newsroom.
Newest → oldest
No matching news yet.